Whole–genome characterization of chemoresistant ovarian cancerAnn‐Marie Patch, Suzanne Manning, Stephen H. Kazakoff et al.|Nature|2015Cited by 1.7k
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, L. Green, Monique Topp et al.|Nature Communications|2018Cited by 299
The molecular origin and taxonomy of mucinous ovarian carcinomaDane Cheasley, Goli Samimi, Matthew J. Wakefield et al.|Nature Communications|2019Cited by 191
Therapeutic options for mucinous ovarian carcinomaKylie L. Gorringe, Clare L. Scott, Dane Cheasley et al.|Gynecologic Oncology|2020Cited by 95
<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian CarcinomasDariush Etemadmoghadam, Walid J. Azar, Ying Lei et al.|Cancer Research|2017Cited by 91